Siegfried Holding AG: Business Overview, Financials & Competitive Analysis
Siegfried Holding AG scores 7/10 on the AskCyborg Cyborg Score (Strong). Established CDMO with strategic positioning in high-growth cell/gene therapy sector, strong earnings growth, and favorable industry tailwinds offset by operational and regulatory risks. In 2024, revenue grew 1.82% to 1.29 billion, with earnings increasing 41.93% to 160.06 million, demonstrating operational leverage. The long-term outlook appears bright as biotechnology and.
What is Siegfried Holding AG's industry? Siegfried Holding AG (siegfried.ch) operates in Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services. AskCyborg classifies Siegfried Holding AG under Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services in its company registry.
Siegfried Holding AG engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. As a global contract development and manufacturing organization, it...
Cyborg Score thesis
Established CDMO with strategic positioning in high-growth cell/gene therapy sector, strong earnings growth, and favorable...
Read the full analyst-debate transcript →Get the Latest Siegfried Holding AG Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSiegfried Holding AG Overview
Pro stress-test →Siegfried Holding AG engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. As a global contract development and manufacturing organization, it derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. The company serves a critical role in the pharmaceutical supply chain with a diversified portfolio spanning multiple therapeutic areas.
Strategic Profile
Pro stress-test →Siegfried continues to strengthen its manufacturing capabilities in the rapidly growing cell and gene therapy market, with its completed facility Dinamiqs enabling end-to-end manufacturing of viral vector gene therapies. The company has a large global footprint with 13 production sites on three continents. The EVOLVE+ strategy and strategic M&A activities are set to enhance growth, expand services, and improve margins, with investments in new technologies and diversification expected to drive revenue stability and efficiency improvements.
Competitive Landscape
Pro stress-test →Siegfried operates as a global contract development and manufacturing organization deriving revenue from long-term supply agreements with biotechnology and pharmaceutical customers. The CDMO space includes major players like Euroapi and others, though Siegfried's differentiation lies in its cell and gene therapy capabilities and diversified manufacturing footprint across multiple continents.
Industry Context
Siegfried Holding AG operates in Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services.
Key facts
Founded: 1873 · Headquarters: Zofingen, Switzerland · Employees: 3,890 · Revenue: $1.29B · Market cap: $4.21B